Divergent Roles of PIK3C3 in KRAS ‐Wild‐Type and KRAS ‐Mutant Advanced Colorectal Cancer: Implications for 5‐Fluorouracil Sensitivity and Prognosis
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.10.2026. Verfasst von Chien-An Chu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fluorouracil, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Cheng Kung University Hospital, National Cheng Kung University.
Abstract (Originalsprache)
Introduction
Phosphatidylinositol 3‐kinase catalytic subunit type 3 (PIK3C3) is central to autophagy, which supports cancer adaptation to environmental stresses and may contribute to drug resistance. KRAS ‐mutant cancers have been reported to require autophagy for survival. We investigated the influence of KRAS mutation status on the roles of PIK3C3 in colorectal cancer (CRC) cell viability and chemosensitivity in vitro, as well as its association with patient prognosis.
Methods
The clinical significance of PIK3C3 expression in relation to KRAS mutation status was evaluated by immunohistochemistry in patients with advanced CRC. Cell viability, colony formation, and spheroid formation assays were performed using CRC cell lines.
Results
In KRAS ‐wild‐type ( KRAS ‐WT) Caco‐2 and Colo320 cells, PIK3C3 and the KRAS/ERK pathway appeared to positively regulate each other. In contrast, PIK3C3 inhibition did not reduce p‐ERK levels or induce significant p62 accumulation in KRAS ‐mutant SW480 and HCT116 cells. PIK3C3 knockdown reduced cell viability but increased resistance to 5‐fluorouracil (5‐FU) in Caco‐2 and Colo320 cells, whereas the opposite effect was observed in SW480 and HCT116 cells. Transfection with a KRAS ‐mutant plasmid sensitized Caco‐2 cells to 5‐FU accompanied by reduced thymidylate synthase (TS) and β‐catenin levels following PIK3C3 inhibition. Clinically, high PIK3C3 expression was associated with KRAS mutation and poorer survival in patients with advanced CRC. Its adverse short‐term prognostic association was more pronounced in KRAS ‐mutant CRC than in KRAS ‐WT CRC.
Conclusion
Based on preclinical in vitro findings, PIK3C3 appears to support KRAS ‐WT and KRAS ‐mutant CRCs in different ways. Notably, PIK3C3 inhibition enhances 5‐FU sensitivity in KRAS ‐mutant CRC cells, potentially through TS regulation, and warrants further investigation as a therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Pathology, School of Medicine, China Medical University, Taichung, Taiwan.
- Center for Precision Medicine, China Medical University Hospital, Taichung, Taiwan.
- Center for Allergy, Immunology, and Microbiome (A.I.M.), China Medical University Hospital, Taichung, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Genomic Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Chien-An Chu, Nan-Haw Chow, Jiu-Yao Wang, Chen Chang, Peng-Chan Lin, Shang-Hung Chen, Ren-Hao Chan, Che-Wei Hsu, Chung-Ta Lee
Förderung
- Ministry of Science and Technology, Taiwan
- National Cheng Kung University Hospital
- National Cheng Kung University
- China Medical University Hospital
- National Science and Technology Council
Zitieren
APA
Chu, C. A., Chow, N. H., Wang, J. Y., Chang, C., Lin, P. C., Yeh, Y. M., Lin, B. W., Wang, Y. W., Dai, Y. H., Chen, Y. L., Chen, P. C., Chen, S. H., Chan, R. H., Ho, C. L., Hsu, C. W., & Lee, C. T. (2026). Divergent Roles of PIK3C3 in KRAS ‐Wild‐Type and KRAS ‐Mutant Advanced Colorectal Cancer: Implications for 5‐Fluorouracil Sensitivity and Prognosis. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72434
Vancouver
Chu CA, Chow NH, Wang JY, Chang C, Lin PC, Yeh YM, et al. Divergent Roles of PIK3C3 in KRAS ‐Wild‐Type and KRAS ‐Mutant Advanced Colorectal Cancer: Implications for 5‐Fluorouracil Sensitivity and Prognosis. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72434
BibTeX
@article{Chu2026,
author = {Chu, Chien-An and Chow, Nan-Haw and Wang, Jiu-Yao and Chang, Chen and Lin, Peng-Chan and Yeh, Yu-Min and Lin, Bo-Wen and Wang, Yi-Wen and Dai, Yun-Hao and Chen, Yi-Lin and Chen, Po-Chuan and Chen, Shang-Hung and Chan, Ren-Hao and Ho, Chung-Liang and Hsu, Che-Wei and Lee, Chung-Ta},
title = {Divergent Roles of PIK3C3 in KRAS ‐Wild‐Type and KRAS ‐Mutant Advanced Colorectal Cancer: Implications for 5‐Fluorouracil Sensitivity and Prognosis},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72434}
}
EUVIMED